On the Frontiers of Breast Cancer Diagnosis and Treatment: Current and Future Directions in a Rapidly Changing Field

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2022 Aug 26

PMID 36013493

Authors

Jimmy T Efird

Charulata Jindal

Tithi Biswas

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BCa) represents a medically heterogeneous group of malignancies, with differing biological and genetic makeups [...].

References

Zhang Y, Ma Y, Zeng Y, Liu Y, He E, Liu Y . A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics. Ann Transl Med. 2022; 9(22):1704. PMC: 8667115. DOI: 10.21037/atm-21-5271. View

Kong S, Liu X, Tan S, Tai J, Phua L, Poh H . Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer. Front Oncol. 2021; 11:698551. PMC: 8322849. DOI: 10.3389/fonc.2021.698551. View

Alhakamy N, Fahmy U, Eldin S, Ahmed O, Aldawsari H, Okbazghi S . Scorpion Venom-Functionalized Quercetin Phytosomes for Breast Cancer Management: In Vitro Response Surface Optimization and Anticancer Activity against MCF-7 Cells. Polymers (Basel). 2022; 14(1). PMC: 8747200. DOI: 10.3390/polym14010093. View

Nair V, Caudrelier J . Hypofractionated radiotherapy for elderly breast cancer patients: from early stages disease to local palliation for unresectable disease. Transl Cancer Res. 2022; 9(Suppl 1):S189-S196. PMC: 8799247. DOI: 10.21037/tcr.2019.09.20. View

Wang L, Jiang Z, Qiu H, Tang W, Duan T, Wang L . Associations between CTLA-4 +49 A/G (rs231775) polymorphism and cancer risk: a meta-analysis based on 52 case-control studies. Int J Clin Exp Med. 2015; 8(5):6835-51. PMC: 4509167. View

Lei J, Wang Y, Bi Z, Xue S, Ou B, Liu K . Intraoperative radiotherapy (IORT) versus whole-breast external beam radiotherapy (EBRT) in early stage breast cancer: results from SEER database. Jpn J Radiol. 2019; 38(1):85-92. DOI: 10.1007/s11604-019-00891-7. View

Prakash O, Hossain F, Danos D, Lassak A, Scribner R, Miele L . Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors. Front Public Health. 2021; 8:576964. PMC: 7783321. DOI: 10.3389/fpubh.2020.576964. View

Davis A, Zhang Q, Gerratana L, Shah A, Zhan Y, Qiang W . Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Breast Cancer Res. 2019; 21(1):137. PMC: 6894208. DOI: 10.1186/s13058-019-1229-6. View

Sartaj A, Qamar Z, Qizilbash F, Annu , Md S, Alhakamy N . Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations. Polymers (Basel). 2021; 13(24). PMC: 8703470. DOI: 10.3390/polym13244400. View

10.

Qi Y, Zhang L, Wang Z, Kong X, Zhai J, Fang Y . Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence. Front Pharmacol. 2021; 12:653521. PMC: 8276035. DOI: 10.3389/fphar.2021.653521. View

11.

Alix-Panabieres C, Pantel K . Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016; 6(5):479-91. DOI: 10.1158/2159-8290.CD-15-1483. View

12.

Stanton S, Disis M . Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016; 4:59. PMC: 5067916. DOI: 10.1186/s40425-016-0165-6. View

13.

Brown A, Buss E, Chin C, Liu G, Lee S, Rao R . Targeted Intraoperative Radiotherapy (TARGIT-IORT) for Early-Stage Invasive Breast Cancer: A Single Institution Experience. Front Oncol. 2022; 12:788213. PMC: 9277011. DOI: 10.3389/fonc.2022.788213. View

14.

Yersal O, Barutca S . Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014; 5(3):412-24. PMC: 4127612. DOI: 10.5306/wjco.v5.i3.412. View

15.

Yedjou C, Sims J, Miele L, Noubissi F, Lowe L, Fonseca D . Health and Racial Disparity in Breast Cancer. Adv Exp Med Biol. 2019; 1152:31-49. PMC: 6941147. DOI: 10.1007/978-3-030-20301-6_3. View

16.

Rodriguez F, Caruana P, de la Fuente N, Espanol P, Gamez M, Balart J . Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules. 2022; 12(6). PMC: 9221343. DOI: 10.3390/biom12060784. View

17.

Giuliano A, Edge S, Hortobagyi G . Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol. 2018; 25(7):1783-1785. DOI: 10.1245/s10434-018-6486-6. View

18.

Ogunleye A, Piyawajanusorn C, Goncalves A, Ghislat G, Ballester P . Interpretable Machine Learning Models to Predict the Resistance of Breast Cancer Patients to Doxorubicin from Their microRNA Profiles. Adv Sci (Weinh). 2022; 9(24):e2201501. PMC: 9403644. DOI: 10.1002/advs.202201501. View

19.

Wilhoit T, Patrick J, May M . Alpelisib: A Novel Therapy for Patients With Mutated Metastatic Breast Cancer. J Adv Pract Oncol. 2021; 11(7):768-775. PMC: 7646628. DOI: 10.6004/jadpro.2020.11.7.9. View

20.

Citgez B, Yigit B, Bas S . Oncoplastic and Reconstructive Breast Surgery: A Comprehensive Review. Cureus. 2022; 14(1):e21763. PMC: 8890601. DOI: 10.7759/cureus.21763. View